WAYNE, Pa., Jan. 18 /PRNewswire/ -- FemmePharma, Inc. is pleased to announce two significant changes to its corporate structure that will enable it to effectively play an expanded role in the growing worldwide market for woman-focused pharmaceutical products.
The first major shift includes the formation of FemmePharma Holding Company, Inc. to house the FemmePharma operating companies and their expanding intellectual property estate. The second change is the creation of a new subsidiary, FemmePharma Global Healthcare, Inc., to support the company's mission of developing drugs for diseases and disorders disproportionately affecting women throughout the world.
"These changes are important because they emphasize the growing global market for treatments that specifically target women and the diseases that disproportionately affect them," explains FemmePharma, Inc. President & CEO, Gerianne Tringali DiPiano. "We are committed to developing and expanding the drugs in our pharmaceutical pipeline, quite simply, because women throughout the world need them, and these changes in our structure will allow us to smoothly transition into a company that can meet these global needs."
Ms. Tringali DiPiano explained that FemmePharma Holding Company will oversee clinical and pharmaceutical development across the company's product lines here in the U.S. and globally. She noted the company will continue to create specialty subsidiaries for its areas of therapeutic focus.
FemmePharma Global Healthcare is engaged in the ongoing development of products in the therapeutic areas of endometriosis, urinary incontinence and mastalgia in other parts of the world.
About FemmePharma, Inc.
FemmePharma was founded by Gerianne Tringali DiPiano in 1996 to target needs within the estimated $70 billion women's healthcare pharmaceutical market. FemmePharma is devoted to developing safe and effective drugs that minimize or eliminate unpleasant side effects associated with many medications by designing them in a manner that is specifically suited to a woman's physiology, with an eye toward the changing needs of women throughout their lives. The company has a number of drugs in development based on its proprietary technologies, including new therapeutic options for urinary incontinence and mastalgia. For more information about FemmePharma, please visit its website at http://www.femmepharmainc.com/.
CONTACT: Kim Groff, FemmePharma, Inc., +1-610-995-0801, ext. 2